Back
4 MIN READ
Although Israel is known for its advanced weaponry and military defense systems, the country is also a leader in scientific research focused on cannabis. Scientists in Israel have been researching the benefits associated with cannabis for the last 50 years and the country’s pro-cannabis standpoint has made it attractive to pharmaceutical and biotech companies.
The growth of the cannabis industry has provided investors with the opportunity to invest in Israeli cannabis companies that trade on the United States stock market.
Although these opportunities are attractive to a lot of investors, many do not want to invest in an OTC-traded company….and now they do not need to do so
A Biotech to Bet on
The market just received a new IPO from a biotech firm that is taking an approach similar to companies such as GW Pharmaceuticals (GWPH) and Zynerba Pharmaceuticals (ZYNE).
The company, Therapix Biosciences Ltd. (TRPX: Nasdaq) was founded in 2004 and listed on the Tel Aviv Stock Exchange (TASE) in early 2014.
TRPX rallied almost 50% during its first day trading on the Nasdaq exchange and the shares continue to trend higher this morning.
About Therapix Biosciences
Therapix Biosciences is a specialty clinical-stage pharmaceutical company led by a team of experienced executives and scientists focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
The company plans to use the net proceeds from its IPO to advance its two leading product candidates for its upcoming planned Phase II clinical trials and for working capital and other general corporate purposes.
Therapix has initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol):
- THX-TS01 targeted to the treatment of Tourette Syndrome
- THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments.
THX-TSO1, Therapix’s leading product candidate is created by using dronabinol and Palmitoylethanolamide (PEA). Dronabinol is a man-made form of cannabis and is the name of the psychoactive compound in cannabis (THC). PEA is a fatty acid that has a natural attraction to the GPR55 and GPR119 cannabinoid receptors. The fatty acid does not bind to the primary endocannabinoid receptors, CB1 and CB2.
A New and Different Biotech Opportunity
Investors and financial institutions have been patiently waiting for new Nasdaq-traded biotech cannabis investment opportunities and we are favorable on the opportunity provided by Therapix.
We expect Therapix to be a profitable investment due to the strong demand for cannabis related investments from investors and financial institutions who want to invest in companies that trade on a national stock exchange (not the OTC).
Important Investor Disclosures
Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners LLC. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional adviceregarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC. StoneBridge Partners LLC receives
All good -- no spamming here.
Comments